Summary
Urotoxic side effects on the kidneys and urinary bladder are a limiting factor in chemotherapy with oxazaphosphorine cytostatics such as cyclophosphamide and ifosfamide. Acrolein was found to be the causative factor which is spontaneously formed in the urine from the primary metabolites eliminated via the kidneys. Sodium 2-mercaptoethanesulfonate (INN: mesna) enables regional detoxification of acrolein in the kidneys and deferent urinary tract. The author reports on the pharmacotherapeutic bases and the mechanism of action of this new combination therapy and its clinical results. The untoward urotoxic side effects can be avoided with mesna without interfering with the chemotherapeutic effect on the tumor.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Brock N (1979) The special position of ifosfamide in the series of cytostatically active oxazaphosphorines. In: Fox BW (ed) Advances im Medical Oncology, Research and Edu- cation, vol 5, Basis for Cancer Therapy 1. Pergamon Press, Oxford New York
Brock N, Stekar J, Pohl J, Niemeyer U, Scheffler G (1979) Acrolein, the causative factor of urotoxic side-effects of cyclophosphamide, ifosfamide, trofosf amide and sufosf amide. Arzneim Forsch 29:659–661
Brock N, Stekar J, Pohl J, Scheef W (1979) Antidot gegen urotoxische Wirkungen der Oxazaphosphorin-Derivate Cyclophosphamid, Ifosfamid und Trofosf amid. Naturwissenschaften 66:60–61
Burkert H, Schnitker J, Fichtner E (1979) Verhütung der Harnwegstoxizität von Oxazaphosphorinen durch einen “Uroprotektor”. Munch Med Wochenschr 121:760–762
Klein HO, Christian E, Coerper C, Klein PJ, Scheef W, Brock N, (1978) Experimental and clinical investigation on the protective effect of 2-mercapto-aethan-sulfon-acid (MAS) on kidneys and urinary bladder during high-dose therapy with ifosfamide (IF) and cyclophos- phamide (CPA). Medical Oncology, Abstr., 4th Annual Meeting Oncology Society, Nice, Dec 2–4, 1978
Scheef W, Klein HO, Brock N, Burkert H, Gunther U, Hoefer-Janker H, Mitrenga D, Schnitker J, Voigtmann R (1979) Controlled clinical studies with an antidote against the urotoxicity of oxazaphosphorines: Preliminary results. Cancer Treat Rep 63:501–505
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1980 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Brock, N. (1980). The Development of Mesna for the Inhibition of Urotoxic Side Effects of Cyclophosphamide, Ifosfamide, and Other Oxazaphosphorine Cytostatics. In: Mathé, G., Muggia, F.M. (eds) Cancer Chemo- and Immunopharmacology. Recent Results in Cancer Research, vol 74. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-81488-4_32
Download citation
DOI: https://doi.org/10.1007/978-3-642-81488-4_32
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-81490-7
Online ISBN: 978-3-642-81488-4
eBook Packages: Springer Book Archive